Bibliography
- ODDS FC: Pathogenic fungi in the 21sL century. Trends Nlicrobiol. (2000) 8:200–201.
- WARNOCK DW: Introduction to the management of fungal infection in the compromised host. In: Fungal Infection in the Compromised patient, 2'd edition. Warnock DW, Richardson MD (Eds.), John Wiley & Sons, Chichester, UK (1990):23–53.
- BECK-SAGU CM, JARWIS WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980–1990.1 Infect. Dis. (1993) 167:1247–1251.
- KIBBLER CC: Epidemiology of fungal infections. In: Principles and Practice of Clinical Mycology Kibbler CC, Mackenzie DWR, Odds FC (Eds.), John Wiley & Sons, Chichester, UK. (1996):13–21.
- AMPEL NM: Emerging disease issues and fungal pathogens associated with HIV infection. Emerg. Infect. Dis. (1996) 2:109–116.
- CHIOU CC, GROLL AH, GONZALEZ CE etal.: Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: clinical manifestations and risk factors. Pediatr. Infect. Dis. J. (2000) 19:729–734.
- CHOCARRO MARTINEZ A, GALINDO F, RUIZ-IRASTORZA G, GONZALEZ LOPEZ A: Risk factors for esophageal candidiasis. Eur. I Chi]. Microbial. Infect. Dis. (2000) 19:96–100.
- PFALLER MA, JONES RN, MESSER SA, EDMOND MB, WENZEL RP: National surveillance of nocosomial blood stream infection due to Candida albicans frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbial. Infect. Dis. (1998) 31:327–332.
- VISCOLI C, GIRMENIA C, MARINUS A etal.: Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Chi]. Infect. Dis. (1999) 28:1071–1079.
- LATGE J-P: Aspergillus furnigatus and aspergillosis. CBI]. Microbial. Rev (1999) 12:310–350.
- •A thorough review on aspergillosis.
- FANOS V, CATALDI L: Amphotericin B- nephrotoxicity: a review.Chernother. (2000) 12:463–470.
- •A comprehensive review of amphotericin's adverse reactions.
- VANDEN BOSSCHE H: Chemotherapy ofhuman fungal infections. In: Modern Selective Fungicides. Lyr H (Ed), Gustav Fisher Verlag, Jena, Germany. (1995):431–484.
- VERMES A, GUCHELAAR HJ, J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antlinicrob. Chernother. (2000) 46:171–179.
- •A good update of flucytosine's properties.
- SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. CBI]. Microbial. Rev (1999) 12:40–79.
- KAUFFMAN CA, CARVER PL: Antifungal agents in the 1990s. Current status and future developments. Drugs (1997) 53:539–549.
- HAROUSSEAU JL, DEKKER AW, STAMATOULLAS-BASTARD A et al.: oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob. Agents Chernother. (2000) 44:1887–1893.
- ODDS FC: Antifungal therapy. In: Principles and Practice of Clinical Mycology Kibbler CC, Mackenzie DWR, Odds FC (Eds.), John Wiley & Sons, Chichester, UK. (1996):35–48.
- •A comprehensive review of the present and future antifungal agents.
- STEVENS DA, HOLMBERG K: to antifungal drugs: Current status and clinical implications. Curr. Opin Antidrifec. Investig. Drugs. (1999) 1:306–317.
- ESPINEL-INGROFF A, WARNOCK DW, VAQUEZ JA, ARTHINGTON-SKAGGS BA: In vitro antifungal susceptibilty methods and clinical implications of antifungal resistance. Med. Mycol. (2000) 38\(Suppl. 1):293–304.
- MARICHAL P: Mechanisms of resistance to azole antifungal compounds. Curr. Opin. Ther. Antidrifec. Irivestig. Drugs. (1999) 1:318–333.
- •Good review of the mechanisms of antifungal resistance.
- WALSH TJ, VIVIANI M-A, E et al.: New targets and delivery systems for antifungal therapy. Med. Mycol. (2000) 38\(Suppl. 1):335–347.
- GROLL AH, WALSH TJ: MK-0991 Merck & Co. Curr. Opin. Anti-infect. Invest. Drugs (1999) 1:334–345.
- ••Excellent overview of the properties ofcaspofungin (MK-0991).
- BENZ F, KNUSEL F, NEUSCH J et al.: Stoffwechsel Produkte von Mikroorganismen. Echinocandin B, emn neuartiges Polypetid- Antibiotikum aus Aspergillus nidularis var, echinulatus: Isolierung und Bausteine. Hely. China. Acta (1974) 57:2459–2477.
- •One of the first papers on echinocandin B.
- HAMMOND ML: Chemical and structure-activity studies of the echinocandin lipopeptides. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc., New York, USA (1993):395–420.
- MIZUNO K, YAGI A, SATOI S, TAKADA M, HAYASHI M: Studies on aculeacin. I. Isolation and characterization of aculeacin A. j Aritibiot. (Tokyo) (1977) 30:297–302.
- DEBONO M, ABBOTT BJ, TURNER JR et al.: Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. NY Acad. Sc. (1988) 544:152–167.
- GORDEE RS, ZECKNER DJ, HOWARDLC, ALBORN WE JR DEBONO M: Anti- Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann. NY Acad. Sc. (1988) 544:294–309.
- PFALLER M. GORDEE R, GERARDEN T, YU M, WENZEL R: Fungicidal activity of cilofungin (LY121019) alone and in with anticapsin or other antifungal agents. Eur. I Chia. 11/licrobiol. Infect. Dis. (1989) 8:564–567.
- ODDS FC: Activity of cilofungin (LY121019) against Candida species in vitro. j Aritimicrob. Chemother (1988) 22:891–897.
- BARTIZAL K, ABRUZZO GK, SCHMATZ DM: Biological activity of the pneumocandins. In: Cutaneous Antifungal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc. New York, USA (1993):421–455.
- ••An excellent review of the biologicalproperties of the first series of pneumocandins.
- GORDEE RS, ZECKNER DJ, ELLIS LF, THAKKAR AL, HOWARD LC: In vitro and in vivo anti- Canctida activity and toxicology of LY121019.j Aritibiot. (Tokyo) (1984) 37:1054–1065.
- BEAULIEU D, TANG J, ZECKNER DJ, PARR TR JR: Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-P-D-glucan synthase. FEMS Microbial. Lett. (1993) 108:133–137.
- GROLL AH, WALSH TJ: Potential new antifungal agents. Curr. Opin. Infect. Dis. (1997) 10:449–458.
- HAWSER S: LY-303366 Eli Lilly & Co. Curr Opin. Anti-infect. Invest. Drugs (1999) 1:353–360.
- ••Overview of the properties of LY-303366.
- KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991 and fluconazole against Caridida species and Cryptococcus rieoformaris. Aritimicrob. Agents. Chemother (1997) 41:1957–1960.
- ESPINEL-INGROFF A: Comparison of invitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. j CBI]. Microbial. (1998) 36:2950–2956.
- •The in vitro characterisation of caspofungin and anidulafungin is described.
- GREEN LJ, MARDER P, MANN LL, CHIO L-C, CURRENT WL: LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Aritimicrob. Agents. Chemother (1999) 43:830–835.
- PETRAITIS V, PETRAITIENE R, GROLLA et al.: Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. (2001) 45:471–479.
- GROLL AH, MICKIENE D, R etal.: Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents. Chemother. (2001) 45:2845–2855.
- VERWEIJ PE, OAKLEY KL, MORRISSEY J, MORRISSEY G, DENNING DW: Efficacy of LY303366 against amphotericin B-susceptible and - resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Aritimicrob. Agents Chemother. (1998) 42:873–878.
- BARTLETT MS, CURRENT WL, GOHEEN MP et al.: Semisynthetic echinocandins affect cell wall deposition of Prieumocystis carinii in vitro and in vivo. Aritimicrob. Agents Chemother. (1996) 40:1811–1816.
- ZORNES LL, STRATFORD RE: Development of a plasma high-performance liquid chromatography assay for LY303366, a lipopeptide antifungal agent and its application in a dog pharmacokinetic study. Chromtogr. Biomed. Li. AppL (1997) 695:381–387.
- IWAMOTO T, FUJIE A, SAKAMOTO K et al.: WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties. _J. Antibiot. (Tokyo) (1994) 47:1084–1091.
- IWAMOTO T, FUJIE A, NITTA K, HASHIMOTO S, OKUHARA M, KOHSAKA M: WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. j Aritibiot. (Tokyo) (1994) 47:1092–1097.
- SCHWARTZ RE: Cell wall active antifungal agents. Expert Opin. Ther. Patents (2001) 11(10:1761–1772.
- FUJIE A, IWAMOTO T, SATO B et al.: FR131535, a novel water-soluble echinocandin-like lipopeptide: synthesis and biological properties. Bioorg. Med. Chem. (2001) 11:399–402.
- FURUTA T, MURAMATSU H, FUJIE A, FUJIHIRA S, ABUDULLAH NR, KOJIMA S: Therapeutic effects of water echinocandin compounds on Prieumacystis pneumonia in mice. Antimicrob.Agerris Chemother (1998) 42:37–39.
- TOMISHIMA M, OHM H, YAMADA A et al.: FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. j Antibiot. (Tokyo) (1999) 52:674–676.
- TAWARA S, IKEDA F, MAKI K et al.: hivitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother (2000) 44:57–62.
- •The in vitro characterisation of micafungin is described.
- UCHIDA K, NISHIYAMA Y, YOKOTA N, YAMAGUCHI H: In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.j Antibiat. (Tokyo) (2000) 53:1175–1181.
- MULLER FM, KURZAI O, HACKER J, FROSCH M, MUHLSCHLEGEL F: Effect of growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. j Antimicrob. Chemother (2001) 48:713–715.
- MIKAMO H, SATO Y, TAMAYA T: In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. j. Antimicrob. Chemother. (2000) 46:485–487.
- CHIOU CC, MAVROGIORGOS N, TILLEM E, HECTOR R, WALSH TJ: Synergy, pharmacodynamics and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob. Agents Chemother. (2001) 45:3310–3321.
- •Excellent paper on the synergy between nildtomycin Z and micafungin.
- GROLL AH, MICKIENE D, PETRAITIS et al.: Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. (2001) 45:3322–3327.
- IKEDA F, WAKAI Y, MATSUMOTO S et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother (2000) 44:614–618.
- •This paper provides a good overview of the broad in vivo activity of micafungin.
- MAESAKI S, HOSSAIN MA, MIYAZAKI Y, TOMONO K, TASHIRO T, KOHNO S: Efficacy of FK463, a (1,3) D glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice. Antimicrob. Agents Chernother. (2000) 44:1728–1730.
- MATSUMOTO S, WAKAI Y, NAKAI T et al.: Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis. Antimicrob. Agents Chemother (2000) 44:619–621.
- ITO M, NOZU R, KURAMOCHI T et al.: Prophylactic effect of FK463, a novel antifungal lipopeptide, against Prieumacystis carinii infection in mice. Antimicrob. Agents Chemother (2000) 44:2259–2262.
- PETTENGELL K, MYNHARDT J, KLUYTS T, SONI P: A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (1999) Abstract No. 1421.
- SCHWARTZ RE, GIACOBBE RA, BLAND JA, MONAGHAN RL: L-671,329, a new antifungal agent. I. Fermentation and isolation.j Antibiat. (To/do) (1989) 42:163–167.
- SCHWARTZ RE, MASUREKAR PS, WHITE RF: Discovery, production process development and isolation of pneumocandin B0. In: Cutaneous Antifurigal Agents. Rippon JW, Fromtling RA (Eds), Marcel Dekker, Inc., New York, USA: (1993)375–393.
- ••Good monograph on the discovery of thepneumocandins.
- SCHMATZ DM, ROMANCHECK MA, PITARELLI LA et al.: Treatment of Prieumacystis carinii pneumonia with 1,3-13-glucan synthesis inhibitors. Proc. Nati Acad. Sci. USA (1990) 87:5950–5954.
- GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs. (2001) 1545–1558.
- ••An excellent review on the properties ofcaspofungin.
- BOUFFARD FA, ZAMBIAS RA, DROPINSKI JF et al.: Synthesis and antifungal activity of novel cationic pneumocandin Bo derivatives.j Med. Chem. (1994) 37:222–225.
- GILL CJ, PACHOLOK C, LYNCH L, KROPP H: In vitro evaluation of the antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob. Agents Chemother. (1995) 39:1070–1076.
- ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of water-soluble pneumocandin analogs L-733560, L-705589 and L-731373 with mouse models of disseminated aspergillosis and cryptococcosis. Antimicrob. Agents Chemother. (1995) 39:1077–1081.
- •Original report on the synthesis of the Merck echinocandins.
- GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on I3-1,3-glucan synthase inhibitors. Expert Opin Investig. Drugs (2001) 10:269–280.
- ••Excellent update on the glucan synthaseand chitin synthase inhibitors.
- KEATING GM, JARVIS B: Caspofungin. Drugs (2001) 61:1121–1129.
- BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother (1997) 41:2326–2332.
- VAZQUEZ JA, LYNCH M, BOUKOV D, SOBEL JD: hi vitro activity of new pneumocandin antifungal L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother (1997) 41:1612–1614.
- PFALLER MA, MESSER SA, GEES et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.. Microbial. (1999) 37:870–872.
- DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of Pneumocandin L-743, 872 against a variety of clinical important molds. Antimicrob. Agents Chemother (1997) 41:1835–1836.
- GONZALEZ GM, TIJERINA R, NAJ VAR LK et al.: Correlation between antifungal susceptibilities of Coccidiaides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45:1854–1859.
- FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptocaccus neaformaris in vitro. Antimicrob. Agents Chemother (1997) 41:331–336.
- DEL POETA M, CRUZ MC, CARDENAS ME et al.: Synergistic activities of bafilomycin Al, fluconazole and the pneumocandin MK-099 1 /caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus rieoformaris. Antimicrob. Agents Chemother. (2000) 44:739–746.
- HEITMAN J, MOVVA NR, HIESTAND PC, HALL MN; FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA (1991) 88:1948–1952.
- CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus. Aritimicrob. Agents Chemother (2000) 44:3302–3305.
- CHILLER T, FARROKHSHAD K, BRUMMER E, STEVENS DA: The interaction of human monocytes, monocyte-derived macrophages and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagri. Microbial. Infect. D (2001) 39:99–103.
- HADJU R, THOMPSON R, JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41:2339–2344.
- GROLL AH, GULLICK BM, R et al.: Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrob. Agents Chemother. (2001) 45:596–600.
- ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob. Agents Chemother. (1997) 41:2333–2338.
- GRAYBILL JR, NAJVAR LK, LUTHER MF, FOTHERGILL AW: Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob. Agents Chemother (1997) 41:1775–1777.
- GRAYBILL JR, BOCANEGRA R, LUTHER M, FOTHERGILL A, RINALDI MJ: Treatment of murine Caridida krusei or Caridida glabrata infection with L-743,872. Antimicrob. Agents Chemother (1997) 41:1937–1939.
- ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother (2000) 44:2310–2318.
- BOWMAN JC, ABRUZZO GK, ANDERSON JW et al.: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother (2001) 45:3474–3481.
- GRAYBILL JR, NAJVAR LK, MONTALBO EM, BARCHIESI FJ, LUTHER MF, RINALDI MO: Treatment of histoplasmosis with MK-0991 (L-743, 872). Antimicrob. Agents Chemother. (1998) 42:151–153.
- KOHLER S, WHEAT LJ, CONNOLLY P etal.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother (2000) 44:1850–1854.
- POWLES MA, LIBERATOR E ANDERSON J et al.: Efficacy of MK991 (L-743,872), a semisynthetic pneumocandin, in murine models of Prieumocystis carinli. Antimicrob. Agents Chemother (1998) 42:1985–1989.
- BALANI SK, XU X, ARISON BH et al.:Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug. Metab. Dispos. (2000) 28:1274–1278.
- SABLE CA, VILLANUEVA A, E et al.: A randomised, double blind multicenter trial of MK-991 (L-743,872) vs. amphotericin B in the treatment of Caridida esophagitis in adults. 37th Iriterscierice Conference on Antimicrobial Agents and Chemotherapy (1997) Abstract No. LB–33.
- NILIUS AM, RANEY PM, HENSEY-RUDLOFF DM, WANG W, LI Q, FLAMM RK: In vitro activity of A-192411.29, a novel antifungal lipopeptide. Antimicrob. Agents Chemother (2000) 44:1242–1246.
- GUNAWARDANA G, RASMUSSEN RR, SCHERR M et al.: Corynecandin: a novel antifungal glycolipid from Coryrieum modonium: j Aritibiot. (Tokyo) (1997) 50:884–886.
- HAWSERS, BORGONOVI M, MARKUS A, ISERT D: Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. Aritibiot. (Tokyo) (1999) 52:305–310.
- HAWSER S, ISLAM K: Comparisons of the effects of fungicidal and fungistatic antifungal agents on the morphogenetic transformation of Caridida albicaris. Antimicrob. Chemother. (1999) 43:411–413.
- DOUGLAS CM, FOOR E MARRINAN JA et al.: The Saccharomyces cerevisiae FKS1 (ETC1) gene encodes an integral membrane protein which is a subunit of 1,3-I3-D-glucan synthase. Proc. Natl. Acad. Sci. USA (1994) 91:12907–12911.
- MAZUR P, MORIN N, BAGINSKY W et al.: Differential expression and function of two homologous subunits of yeast 1,3-I3-D-glucan synthase. Mol. Cell Biol. (1995) 15:5671–5681.
- MAZUR P, BAGINSKY W: In vitro activityof 1,3-13-D-glucan synthase requires the GTP-binding protein Rho 1. j Biol. Chem. (1996) 211:14604–14609.
- INOUE SB, QADOTA H, ARISAWA M, WATANABE T, OHYA Y: Prenylation of Rho lp is required for activation of yeast 1,3- P-D-glucan synthase. j Biol. Chem. (1999) 274:38119–38124.
- •Excellent paper on the geranylisation of Rholp.
- MIO T, SHIMIZU MA, TACHIBANA Y et al.: Cloning of the Candida albicaris homologue of Saccharomyces cerevisiae CSCII FKS1 and its involvement in 1,3-13-D-glucan synthesis. j Bacteria. (1997) 179:4096–4105.
- DOUGLAS CM, D'IPPOLITO JA, SHEI GJ et al.: Identification of the FKS1 gene of Caridida albicaris as the essential target of 1,3 13 D glucan synthase inhibitors. Aritimicrob. Agents Chemother. (1997) 41:2471–2479.
- KOTTOM TJ, LIMPER AH: Cell wall assembly by Prieumocystis caririii. Evidence for a uinique Gsc-1 subunit mediating 1,3-3-D-glucan deposition. j Biol. Chem. (2000) 275:40628–40634.
- THOMPSON JR, DOUGLAS CM, LI W et al.: A glucan synthase FKS1 homolog in Cryptococcus rieoformaris is single copy and encodes an essential function. j Bacterial. (1999) 181:444–453.
- •Important paper on glucan synthase of C. neoformans.
Websites
- www.prnewswire.com 29 January 2001.
- www.versicor.com